Biophytis Completes a EUR Two Million B Round Financing
News Oct 04, 2012
Biophytis has announced that it has raised EUR two million (USD 2.6M) in a B round. Metabrain Research, a spin-off of Merck Serono based in Chilly-Mazarin (south of Paris) joined existing investors Seventure partners and CM-CIC Capital Prive in this round.
This funding will enable Biophytis to continue the development of its pipeline of nutraceuticals and drug candidates through two collaborative projects with Metabrain Research.
The first project, SARCOB, targets the treatment of sarcopenic obesity, in partnership with the Myology Institute and Institute of Cardio-metabolism and Nutrition, both at the University of Pierre and Marie Curie (UPMC), and France’s national agricultural research institute, INRA.
The second, MACULIA, focuses on treating age-related macular degeneration, in collaboration with UPMC’s Institut de la Vision and Iris Pharma, a contract research organization dedicated to ophthalmology.
Biophytis leads these two projects, which are sponsored by the Medicen competitivity cluster in the Paris region and which benefit from grants of EUR 2.3 million from a number of European and French local and national government bodies.
“The arrival of Metabrain Research as a shareholder marks a step change in a partnership that we have pursued for several years in the SARCOB project,” said Stanislas Veillet, CEO and founder of Biophytis.
Veillet continued, “It will reinforce our capacity to develop drug candidates derived from our portfolio of nutraceutical active substances, with the aim of signing co-development contracts with pharmaceutical companies.”
“The worldwide market of nutrition, where food and drugs meet, has already reached EUR 120 billion annual revenues and is growing at ten per cent a year,” said Isabelle de Cremoux, general manager at Seventure partners.
Cremoux continued, “This makes it very attractive to many industry players. Biophytis is a pioneer in this field and this financing will allow it to accelerate its development with a strategy targeting both drugs and nutrition.”
“We believe the strategic partnership between our two companies in both the scientific and marketing fields will allow us to develop a portfolio of innovative projects,” said Valerie Autier, CEO of Metabrain Research. “We will be able to offer full coverage of metabolic diseases through a joint nutraceutical and pharmaceutical approach.”
The French and European organizations that are providing grants to the SARCOB and MACULIA projects are FUI (Fonds Unique Interministeriel, a cross-ministry funding body), the European Regional Development Fund, the Essonne and Seine-Saint-Denis departments, the Ile de France region and the city of Paris.
Nanotexturing Creates Bacteria-Killing Spikes on Stainless Steel SurfacesNews
By using an electrochemical etching process on a common stainless steel alloy, researchers have created a nanotextured surface that kills bacteria while not harming mammalian cells. If additional research supports early test results, the process might be used to attack microbial contamination on implantable medical devices and on food processing equipment made with the metal.READ MORE
Microbes Help Turn Greek Yogurt Waste Into FuelNews
Consumers across the world enjoy Greek yogurt for its taste, texture, and protein-packed punch. Reaching that perfect formula, however, generates large volumes of food waste in the form of liquid whey. Now researchers have found a way to use bacteria to turn the leftover sugars and acids from Greek yogurt into molecules that could be used in biofuels or safe feedstock additives.READ MORE
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE